Merus NV
MRUS65.382USD
-0.178-0.27%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
4.52BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Merus NV Unternehmen
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Unternehmensinformationen
BörsenkürzelMRUS
Name des UnternehmensMerus NV
IPO-datumMay 19, 2016
CEODr. Sven Ante (Bill) Lundberg, M.D.
Anzahl der mitarbeiter260
WertpapierartOrdinary Share
GeschäftsjahresendeMay 19
AddresseUppsalalaan 17, 3rd & 4th floor
StadtUTRECHT
BörseNASDAQ Global Market Consolidated
LandNetherlands
Postleitzahl3584 CT
Telefon31850162500
Websitehttps://merus.nl/
BörsenkürzelMRUS
IPO-datumMay 19, 2016
CEODr. Sven Ante (Bill) Lundberg, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
7.55%
Wellington Management Company, LLP
6.34%
Commodore Capital LP
6.01%
RTW Investments L.P.
5.60%
Paradigm BioCapital Advisors LP
4.77%
Other
69.72%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
7.55%
Wellington Management Company, LLP
6.34%
Commodore Capital LP
6.01%
RTW Investments L.P.
5.60%
Paradigm BioCapital Advisors LP
4.77%
Other
69.72%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
35.42%
Hedge Fund
34.84%
Investment Advisor
23.80%
Corporation
1.96%
Research Firm
1.56%
Venture Capital
1.48%
Private Equity
1.43%
Individual Investor
0.38%
Pension Fund
0.36%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
409
75.54M
101.47%
-10.37M
2025Q1
420
74.82M
101.12%
-10.15M
2024Q4
398
74.69M
108.18%
-7.45M
2024Q3
373
72.99M
107.03%
-6.71M
2024Q2
355
69.91M
103.77%
+7.77M
2024Q1
315
57.35M
97.63%
-5.32M
2023Q4
282
57.36M
99.41%
-5.55M
2023Q3
268
57.60M
100.50%
+2.76M
2023Q2
260
49.90M
100.83%
+114.35K
2023Q1
250
43.88M
95.34%
-4.11M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
5.62M
7.55%
-39.01K
-0.69%
Mar 31, 2025
Wellington Management Company, LLP
4.72M
6.34%
+1.22M
+34.90%
Mar 31, 2025
Commodore Capital LP
4.47M
6.01%
+598.66K
+15.45%
Mar 31, 2025
RTW Investments L.P.
4.17M
5.6%
--
--
Mar 31, 2025
Paradigm BioCapital Advisors LP
3.55M
4.77%
+184.36K
+5.47%
Apr 03, 2025
Deerfield Management Company, L.P.
3.17M
4.26%
+201.14K
+6.77%
Mar 31, 2025
Avoro Capital Advisors LLC
3.00M
4.03%
+875.00K
+41.18%
Mar 31, 2025
Samlyn Capital, LLC
2.38M
3.2%
-288.75K
-10.82%
Mar 31, 2025
Franklin Advisers, Inc.
1.94M
2.6%
+3.50K
+0.18%
Mar 31, 2025
Holocene Advisors, LP
1.87M
2.52%
-6.39K
-0.34%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Tema Oncology ETF
3.92%
ALPS Medical Breakthroughs ETF
2.65%
Invesco Dorsey Wright Healthcare Momentum ETF
1.51%
Harbor Health Care ETF
1.1%
First Trust IPOX Europe Equity Opportunities ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
JPMorgan Healthcare Leaders ETF
0.62%
ProShares Ultra Nasdaq Biotechnology
0.41%
Invesco Nasdaq Biotechnology ETF
0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
0.39%
Mehr Anzeigen
Tema Oncology ETF
Anteil3.92%
ALPS Medical Breakthroughs ETF
Anteil2.65%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil1.51%
Harbor Health Care ETF
Anteil1.1%
First Trust IPOX Europe Equity Opportunities ETF
Anteil1.04%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.85%
JPMorgan Healthcare Leaders ETF
Anteil0.62%
ProShares Ultra Nasdaq Biotechnology
Anteil0.41%
Invesco Nasdaq Biotechnology ETF
Anteil0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
Anteil0.39%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
